Biotron is now focused on progressing BIT225 into Phase Ib/IIa clinical trials in both HIV and HCV infected subjects. The completed Phase I clinical trial in healthy volunteers will support the trials in these two patient populations, which significantly reduces the costs and timelines of Biotron's clinical development program. Trial designs and regulatory and ethics submissions are in final review for two trials, one in HIV and one in HCV populations and, subject to regulatory and ethics approvals, with likely commencement of these trials in the second quarter of 2008 and concluding during third quarter of 2008.
BIT Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
